The abstract is read at the publisher; the summary is JClub's.
In a single-center phase II trial for clear-cell renal cell carcinoma, [18F]RCCB6 PET/CT detected metastases with 94.2% sensitivity across 1,221 extrarenal lesions.
- Why it matters: Metastatic detection in ccRCC remains challenging, and better lesion-level accuracy is needed to guide treatment decisions more reliably than existing PET and conventional imaging.
- What they did: The study screened 291 patients and imaged 150 with confirmed or suspected ccRCC using [18F]RCCB6 PET/CT, then compared results head-to-head with [18F]FDG PET/CT and conventional imaging.
- The result: [18F]RCCB6 PET/CT showed higher sensitivity and specificity than [18F]FDG PET/CT (90.5% vs. 41.1%; 81.4% vs. 24.3%) and conventional imaging (90.8% vs. 75.1%; 81.6% vs. 56.6%), correlated with CD70 expression (r = 0.843; P < 0.001), and changed management in 58.7% of patients.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.